Celldex Therapeutics Inc. (NASDAQ:CLDX) options contracts experienced a new 90-day record for call contracts where a total of 5,803 call contracts were traded in the busy trading session. The contract spread yielded a 0.58 put/call ratio where 1.7 call contracts were traded for each put contract. Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock performance was 0.07% in last session and finished the day at $13.73. Traded volume was 4.19million shares in the last session and the average volume of the stock remained 2.40million shares. The beta of the stock remained 2.41. Celldex Therapeutics, Inc. (NASDAQ:CLDX) insider ownership is 0.10%.
Shares of Dyax Corp. (NASDAQ:DYAX) saw a large increase in short interest in January. As of March 31st, there was short interest totaling 4,701,750 shares, an increase of 71.4% from the March 14th total of 2,742,925 shares. Dyax Corp. (NASDAQ:DYAX) dropped -2.78 percent to $6.64 Tuesday on volume of 3.37million shares. The intra-day range of the stock was $6.15 to $6.94. Dyax Corp. (NASDAQ:DYAX) has a market capitalization of $901.32million.
Insmed Incorporated (NASDAQ:INSM) will present at the 13th Annual Needham & Co. Healthcare Conference at the Westin Grand Central Hotel in New York City. Insmed Incorporated (NASDAQ:INSM)’s stock on Apr 15, 2014 reported a decrease of -7.30% to the closing price of $12.57. Its fifty two weeks range is $7.08 -$22.29. The total market capitalization recorded $493.55million. The overall volume in the last trading session was 2.07million shares. In its share capital, INSM has 39.27million outstanding shares.
Novavax, Inc. (NASDAQ:NVAX) is a $805 million biotech that develops vaccines for a number of diseases. The stock is currently in a pullback, but this is not surprising because it is happening everywhere in the healthcare sector. But even so, the pullback in Novavax, Inc. (NASDAQ:NVAX) only creates a buying opportunity for long-term outlook investors. On Tuesday, shares of Novavax, Inc. (NASDAQ:NVAX) dropped -0.81% to close the day at $3.69. Company return on investment (ROI) is -36.40% and its monthly performance is recorded as -29.85%. Novavax, Inc. (NASDAQ:NVAX) quarterly revenue growth is -39.71%.